Shire PLC (SHPG) Shares Sold by MML Investors Services LLC
MML Investors Services LLC trimmed its holdings in Shire PLC (NASDAQ:SHPG) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,746 shares of the biopharmaceutical company’s stock after selling 92 shares during the quarter. MML Investors Services LLC’s holdings in Shire PLC were worth $289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in SHPG. Hartford Financial Management Inc. boosted its position in shares of Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Shire PLC during the second quarter worth approximately $171,000. Stephens Inc. AR acquired a new stake in Shire PLC during the first quarter worth approximately $179,000. Quantbot Technologies LP acquired a new stake in Shire PLC during the first quarter worth approximately $182,000. Finally, Tower Research Capital LLC TRC grew its stake in Shire PLC by 45.3% during the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 350 shares during the period. 19.28% of the stock is currently owned by institutional investors.
Shares of Shire PLC (NASDAQ SHPG) opened at 153.14 on Monday. Shire PLC has a 1-year low of $139.36 and a 1-year high of $198.58.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, equities analysts expect that Shire PLC will post $14.93 EPS for the current year.
The business also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s payout ratio is currently 41.07%.
COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/02/shire-plc-shpg-shares-sold-by-mml-investors-services-llc.html.
A number of equities research analysts have weighed in on SHPG shares. BidaskClub upgraded Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. ValuEngine raised Shire PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. HSBC Holdings plc upgraded Shire PLC from a “reduce” rating to a “hold” rating in a report on Thursday, July 6th. Royal Bank Of Canada set a $218.00 price target on Shire PLC and gave the stock a “buy” rating in a report on Thursday, June 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $216.00 price objective (down previously from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $220.08.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.